Company intelligence / Profile preview
Shenzhen Geno-Immune Medical Institute
Shenzhen, Guangdong, Chinaszgimi.org ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
GIMI has over two decades of R&D in immune therapies. Its lead CAR-T programs are in Phase II for blood cancers and solid tumors. The institute’s fourth-generation ‘4SCAR’ CAR-T cells have demonstrated high safety profiles with no serious cytokine release syndrome or neurotoxicity reported to date. Early studies combining mesenchymal stem cells with CAR-Ts for autoimmune disease are ongoing.
- Therapeutic areas
- OncologyImmunologyHematology
- Modalities
- CAR-T cell therapyGene therapyCell therapyMesenchymal stem cells (MSCs)
- Industry
- Biotech
02
Drug pipeline
55 assets54 more assets in the full pipeline.
Beyond the preview
Go deeper on Shenzhen Geno-Immune Medical Institute.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shenzhen Geno-Immune Medical Institute.